Microsoft Corporation (MSFT)
NASDAQ: MSFT · Real-Time Price · USD
520.58
-8.66 (-1.64%)
At close: Aug 13, 2025, 4:00 PM
521.91
+1.33 (0.26%)
After-hours: Aug 13, 2025, 7:59 PM EDT
Silk Road Medical Stock Forecast
Stock Price Forecast
The 28 analysts that cover Silk Road Medical stock have a consensus rating of "Strong Buy" and an average price target of $599.79, which forecasts a 15.22% increase in the stock price over the next year. The lowest target is $475 and the highest is $675.
Price Target: $599.79 (+15.22%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Silk Road Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 13 | 13 | 13 | 12 | 12 |
| Buy | 17 | 16 | 16 | 14 | 13 | 16 |
| Hold | 2 | 1 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 31 | 30 | 32 | 30 | 28 | 30 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $600 → $675 | Strong Buy | Maintains | $600 → $675 | +29.66% | Jul 31, 2025 |
| DA Davidson | DA Davidson | Strong Buy Maintains $600 → $650 | Strong Buy | Maintains | $600 → $650 | +24.86% | Jul 31, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $500 → $650 | Buy | Maintains | $500 → $650 | +24.86% | Jul 31, 2025 |
| Barclays | Barclays | Buy Maintains $550 → $625 | Buy | Maintains | $550 → $625 | +20.06% | Jul 31, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $525 → $640 | Buy | Maintains | $525 → $640 | +22.94% | Jul 31, 2025 |
Financial Forecast
Revenue This Year
323.19B
from 281.72B
Increased by 14.72%
Revenue Next Year
369.79B
from 323.19B
Increased by 14.42%
EPS This Year
15.39
from 13.64
Increased by 12.85%
EPS Next Year
18.00
from 15.39
Increased by 16.91%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 355.8B | 439.3B | 450.3B | ||
| Avg | 323.2B | 369.8B | 418.9B | ||
| Low | 300.9B | 333.4B | 392.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 26.3% | 35.9% | 21.8% | ||
| Avg | 14.7% | 14.4% | 13.3% | ||
| Low | 6.8% | 3.2% | 6.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 17.36 | 22.25 | 22.98 | ||
| Avg | 15.39 | 18.00 | 21.18 | ||
| Low | 13.98 | 16.16 | 19.59 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 27.3% | 44.5% | 27.7% | ||
| Avg | 12.9% | 16.9% | 17.7% | ||
| Low | 2.5% | 5.0% | 8.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.